Literature DB >> 12007525

Targets for therapy of the painful bladder.

Alan J Wein1, Philip M Hanno.   

Abstract

Interstitial cystitis is an elusive disorder. Without a defining etiology and distinctive pathophysiology, diagnosis is made on an exclusionary basis. Treatment strategies for the disease vary, as do estimates of its prevalence. Nevertheless, advances are being made in understanding this disease. Basic research is helping to define rational treatment approaches for interstitial cystitis, and new therapies based on the findings of such research are being developed. This article reviews the theories of the etiology of interstitial cystitis and reviews the evidence for clinical effectiveness of various treatments.

Entities:  

Mesh:

Year:  2002        PMID: 12007525     DOI: 10.1016/s0090-4295(01)01640-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium.

Authors:  Bikramjit Chopra; Stacey R Barrick; Susan Meyers; Jonathan M Beckel; Mark L Zeidel; Anthony P D W Ford; William C de Groat; Lori A Birder
Journal:  J Physiol       Date:  2004-12-02       Impact factor: 5.182

Review 2.  Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

Authors:  Anthony P D W Ford; Joel R Gever; Philip A Nunn; Yu Zhong; Joseph S Cefalu; Michael P Dillon; Debra A Cockayne
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis.

Authors:  P K Matsuoka; J M Haddad; A M Pacetta; E C Baracat
Journal:  Int Urogynecol J       Date:  2012-05-09       Impact factor: 2.894

4.  Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis.

Authors:  Yi-Song Lv; Hui-Liang Zhou; Hou-Ping Mao; Rui Gao; Yan-Dong Wang; Xue-Yi Xue
Journal:  Int Urogynecol J       Date:  2012-05-11       Impact factor: 2.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.